ijms-logo

Journal Browser

Journal Browser

Integrative Oncology: From the Lab to New Therapeutic Possibilities—2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 2165

Special Issue Editors


E-Mail
Guest Editor
Association for Research on Integrative Oncology Therapies (ARTOI), Via Ludovico Micara, 73, 00165 Rome, Italy
Interests: cancer; cytoskeleton; bacterial protein toxins; mitochondria; Rho GTPases; toxins as therapeutics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Translational Pharmacology, National Council of Research (CNR), Via Fosso del Cavaliere, 00133 Rome, Italy
Interests: anti-oxidant; anti-inflammatory; immunomodulating; anti-aging; anti-tumor effects of natural compounds of plant origin
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Integrative oncology, a holistic and patient-centered approach, may help to support the health of patients with cancer, as demonstrated by multiple studies that have shown the benefits and potential of complementary health therapies in addition to conventional cancer care. For these reasons, several scientific associations are now focused on integrative oncology with the aim of changing the paradigm of cancer from 'incurable' to 'sustainable, thus offering new therapeutic options.

In this Special Issue, we attempt to reflect part of the research activity in the field of integrative oncology. The focus will be placed on those findings relevant to clinical cancer research and supported by cellular and molecular in vitro studies. Moreover, a growing number of proofs highlights the strong connection between the human intestinal microbiota and the etiology of colorectal cancer, as well as recent studies are focused on the mechanisms at the basis of the effects of natural products, used to manage the adverse reactions in cancer patients. Hence, the main subjects of this Special Issue will comprise these emergent topics, underlining the role of diet, immune response and epigenetic in cancer therapy and prevention.

The Special Issue will also include articles from the 2nd WORLD CONGRESS OF INTEGRATIVE MEDICINE AND HEALTH CONGRESS (https://icimcongress.org/), which will be held in Rome, Italy, 20–23 September 2023. Therefore, articles on Integrative Medicine, even if not strictly linked to the cancer topic, will also be taken into consideration.

Prof. Dr. Carla Fiorentini
Dr. Maria Pia Fuggetta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • integrative oncology
  • cancer therapy
  • cancer prevention
  • natural products
  • microbiota
  • epigenetics on cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1675 KiB  
Review
Resources for Human Health from the Plant Kingdom: The Potential Role of the Flavonoid Apigenin in Cancer Counteraction
by Laura Fossatelli, Zaira Maroccia, Carla Fiorentini and Massimo Bonucci
Int. J. Mol. Sci. 2024, 25(1), 251; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms25010251 - 23 Dec 2023
Viewed by 1712
Abstract
Apigenin is one of the most widespread flavonoids in the plant kingdom. For centuries, apigenin-containing plant preparations have been used in traditional medicines to treat diseases that have an inflammatory and/or degenerative component. In the 1980s, apigenin was proposed to interfere with the [...] Read more.
Apigenin is one of the most widespread flavonoids in the plant kingdom. For centuries, apigenin-containing plant preparations have been used in traditional medicines to treat diseases that have an inflammatory and/or degenerative component. In the 1980s, apigenin was proposed to interfere with the process of carcinogenesis. Since then, more and more evidence has demonstrated its anticancer efficacy, both in vitro and in vivo. Apigenin has been shown to target signaling pathways involved in the development and progression of cancer, such as PI3K/Akt/mTOR, MAPK/ERK, JAK/STAT, NF-κB, and Wnt/β-catenin pathways, and to modulate different hallmarks of cancer, such as cell proliferation, metastasis, apoptosis, invasion, and cell migration. Furthermore, apigenin modulates PD1/PD-L1 expression in cancer/T killer cells and regulates the percentage of T killer and T regulatory cells. Recently, apigenin has been studied for its synergic and additive effects when combined with chemotherapy, minimizing the side effects. Unfortunately, its low bioavailability and high permeability limit its therapeutic applications. Based on micro- and nanoformulations that enhance the physical stability and drug-loading capacity of apigenin and increase the bioavailability of apigenin, novel drug-delivery systems have been investigated to improve its solubility. Full article
Show Figures

Figure 1

Back to TopTop